Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MedImmune signs with Infinity

September 4, 2006 | A version of this story appeared in Volume 84, Issue 36

MedImmune and Infinity Pharmaceuticals will collaborate to develop small-molecule cancer drugs targeting heat shock protein 90 (Hsp90) and the Hedgehog signaling pathway. Infinity will receive a $70 million up-front fee in exchange for shared rights to its Hsp90 and Hedgehog pathway product development programs, and it could receive an additional $430 million in milestones as products progress toward commercialization. The deal includes IPI-504, an Hsp90 inhibitor that is in Phase I studies for multiple myeloma and gastrointestinal tumors. The companies plan to initiate clinical testing of an oral formulation of IPI-504 in the next 12-18 months.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.